Novel screening of monoclonal antibody-based therapeutics (mAbs) by LC-MS/MS
Introduce more specificity into your projects for greater sensitivity and better method performance.
Drastically decrease the lead time for bioanalysis with our novel LC-MS/MS workflow that can be applied to all human IgG-based therapeutics.
Initiate projects quickly
Eliminate upfront reagents
Conduct parallel work
Get rapid and sensitive quantitation of human mAbs in serum from sera of nonclinical species
Our hybrid LC-MS/MS assay permits rapid and sensitive quantitation of human mAbs in serum from sera of nonclinical species. In addition, the broad specificity of the antiserum for IgG subclasses allows this assay to function in a plug-and-play manner with minimal optimization for efficient support of nonclinical PK of different monoclonal-based therapeutics and ADCs across nonclinical species.
What's next?
What's next in the development pipeline for this novel screening method? We plan to expand scope to include additional mAbs and biotherapeutics containing human light chains. Also, check in with us as we investigate additional signature peptides by LC-MS/ MS corresponding to conserved sequences of IgG2, IgG3.
Brought to you by Veloxity Labs and
B2S Life Sciences
This innovative workflow was proudly developed in partnership between Veloxity Labs, LLC and B2S Life Sciences, LLC.
A special thank you to the following individuals for their significant contributions to this workflow:
-
B2S Life Sciences: Adam S. Kinne, Elijah S. Parmer, Sanofar J. Abdeen, Ronald R. Bowsher
-
Veloxity Labs: Mitch Johnson, Shane Needham, Colt Cookson
